La vendita allo scoperto per GlycoMimetics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di GlycoMimetics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

GlycoMimetics (NASDAQ:GLYC) Azioni, Report sulle vendite allo scoperto

GlycoMimetics

GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.

GlycoMimetics Inc

News

Management

GLYC

GlycoMimetics Anticipates Recognizing About $3.6M In Total Charges In Connection With Headcount Reduction, A Restructuring That Includes A Reduction In Company's Workforce By 26 Employees, Or ~80% Of Its Headcount

TD Cowen analyst Boris Peaker downgrades GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) from Buy to Hold.

Downgrades

Analyst Ratings

TD Cowen Downgrades GlycoMimetics to Hold

GlycoMimetics To Conduct Additional Clinical Trial For Uproleselan In R/R Acute Myeloid Leukemia After FDA Meeting; Initiates Strategic Review And Corporate Restructuring, Reducing Workforce By 80%; Engages Lucid Capital Markets As Strategic Advisor; Advancing Phase 2/3 Study Of Uproleselan In Newly Diagnosed AML Patients With NCI And Alliance For Clinical Trials; Cash Expected To Fund Company Into Q2 2025

On June 21, GlycoMimetics Got Notice From Nasdaq, Co Is Not In Compliance With Nasdaq's Listing Rule 5450(a)(1)

GlycoMimetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) stock is moving higher Monday after its chief medical officer disclosed the <a href="https://www.benzinga.com/quote/GLYC/insider-trades">purchase of company stock. </a>
The Details: On Tuesday, the chief medical officer Edwin Rock disclosed in a Form4 that he bought 305,000 shares of the company.
Rock purchased the shares at an average price of 26 cents.
How To Buy GlycoMimetics Stock
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like <a href="https://www.benzinga.com/quote/GLYC">GlycoMimetics</a>&#8216;s page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
For example, if you're looking to earn an annualized return of 21.91%, you'll need to buy a share of Simplify Exchange Traded Funds Simplify Propel Opportunities ETF by the Jun. 25, 2024. Once done, you can expect to receive a nominal payout of $1.25 on Jun. 28, 2024.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/GLYC">GlycoMimetics</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
Related Link: <a href="http://Related Link: 5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More">5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More</a>
GLYC Price Action: At the time of publication, GlycoMimetics shares is trading 20% higher at 32 cents, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: 8676549 from Pixabay.

Movers

Why GlycoMimetics Stock is Trading Higher Monday

WIIM

GlycoMimetics shares are trading higher after the company disclosed that Chief Medical Officer Edwin Rock bought 305,000 shares at an average price of $0.26 per share.

Insider Trades

GlycoMimetics Form 4 Filing Shows CMO Edwin Rock Bought 305,000 Shares At An Average Price Of $0.26/Share

The Dow Jones index closed higher by around 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#8217;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Vaxart</h3>
<ul>
<li>The Trade: Vaxart, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>) Director W. Mark Watson <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 20,000 shares</a> at an average price of $0.68. To acquire these shares, it cost around $13,578.</li>
<li>What's Happening: Vaxart announced Monday that proceeds from a recent offering combined with reimbursements under its Project NextGen award are expected to extend the company's cash runway into 2026.</li>
<li>What Vaxart Does: Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases.</li>
</ul>
<h3 class="wp-block-heading">Clover Health Investments</h3>
<ul>
<li>The Trade: Clover Health Investments, Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) Director Vivek Garipalli <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 877,567 shares</a> at an average price of $1.14. To acquire these shares, it cost around $1 million.</li>
<li>What's Happening: On May 7, Clover Health Investments reported better than expected first-quarter financial results.</li>
<li>What Clover Health Investments Does: Clover Health Investments Corp is a healthcare technology company.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/06/39410338/top-4-consumer-stocks-that-may-keep-you-up-at-night-this-month">Top 4 Consumer Stocks that May Keep You Up At Night This Month</a>
<h3 class="wp-block-heading">Alset</h3>
<ul>
<li>The Trade: Alset Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEI#NASDAQ">AEI</a>) CEO Heng Fai Ambrose Chan <a href="https://www.benzinga.com/sec/insider-trades/">acquired a total of 50,000 shares</a> at an average price of $1.20. The insider spent around $60,000 to buy those shares. </li>
<li>What's Happening: The company&#8217;s stock gained around 125% over the past month.</li>
<li>What Alset Does: Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea.</li>
</ul>
<h3 class="wp-block-heading">GlycoMimetics</h3>
<ul>
<li>The Trade: GlycoMimetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) SVP Finance, CFO Brian M. Hahn <a href="https://www.benzinga.com/quote/aei/analyst-ratings">acquired a total of 17,500 shares</a> at an average price of $0.25. The insider spent around $4,335 to buy those shares.</li>
<li>What's Happening: On June 4, GlycoMimetics announced results from its Phase 3 study of uproleselan in R/R AML demonstrating a clinically meaningful improvement in median overall survival..</li>
<li>What GlycoMimetics Does: GlycoMimetics Inc is a clinical-stage biotechnology company.</li>
</ul>
Don&#8217;t forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>

Long Ideas

Penny Stocks

Pre-Market Outlook

Markets

Trading Ideas

CLOV

VXRT

$1M Bet On This Penny Stock? Check Out These 4 Stocks Under $2 Insiders Are Aggressively Buying

HC Wainwright &amp; Co. analyst Edward White reiterates GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) with a Neutral.

Reiteration

HC Wainwright & Co. Reiterates Neutral on GlycoMimetics

GlycoMimetics shares are trading higher after the company announced results from its Phase 3 study of uproleselan in R/R AML demonstrating a clinically meaningful improvement in median overall survival.

<ul>
<li>Company exploring path forward for uproleselan in multiple AML settings based on observed efficacy results, including clinically meaningful results in primary refractory AML, and significant unmet patient need</li>
<li>Uproleselan demonstrated a clinically meaningful improvement in median overall survival (mOS) for patients with primary refractory AML; mOS was 31.2 months for the uproleselan arm compared to 10.1 months for the placebo arm in this subgroup</li>
<li>Adverse events for uproleselan were consistent with known side effect profiles of chemotherapy used in the study</li>
<li>Advancing discussions with the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology for Phase 2/3 study of uproleselan with chemotherapy in older adults with frontline AML</li>
</ul>

Biotech

Health Care

General

GlycoMimetics Shares Detailed Results From Its Pivotal Phase 3 Study Of Uproleselan In Relapsed/Refractory Acute Myeloid Leukemia

GlycoMimetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that it will host a key opinion leader event on Tuesday, June 4, 2024, at 8:30am ET to provide a comprehensive overview of data from the company's pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) acute myeloid leukemia (AML).
The event will feature the study's principal investigator Daniel DeAngelo, M.D., Ph.D., Professor of Medicine, Harvard Medical School, and Chief of the Division of Leukemia, Dana-Farber Cancer Institute, who will discuss results from the pivotal Phase 3 study of uproleselan, along with the current AML treatment landscape and unmet patient need.
To access the event by phone, please go to this <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fregister.vevent.com%2Fregister%2FBI695ec655bd7b4828843adee1f4535ced&amp;esheet=54022011&amp;newsitemid=20240529592940&amp;lan=en-US&amp;anchor=registration+link&amp;index=1&amp;md5=3f3bd1399b6a1408a299c7578774ebf3">registration link</a> to obtain the dial in details. Participants are encouraged to connect 15 minutes in advance of the scheduled start time.
A live webcast of the call will be available on the "<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.glycomimetics.com%2Fevents-presentations&amp;esheet=54022011&amp;newsitemid=20240529592940&amp;lan=en-US&amp;anchor=Investors&amp;index=2&amp;md5=d6486884015c7d92f21558cd7dfa6668">Investors</a>" tab on the GlycoMimetics website. A webcast replay will be available for 30 days following the call.

GlycoMimetics To Host Leader Event To Review Results From Pivotal Phase 3 Study Of Uproleselan In Relapsed/Refractory Acute Myeloid Leukemia On June 4, 2024

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Monday.
The Dow traded up 0.35% to 38,811.58 while the NASDAQ rose 0.95% to 16,309.74. The S&amp;P 500 also rose, gaining, 0.82% to 5,169.93.
Leading and Lagging Sectors Energy shares rose by 1.5% on Monday.
In trading on Friday, consumer staples shares fell by 0.4%.
Top Headline
Shares of Spirit Airlines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAVE#NYSE">SAVE</a>) fell sharply during Monday&#8217;s session after reporting first-quarter results.
Spirit Airlines reported a first-quarter fiscal 2024 revenue decline of 6.2% Y/Y to $1.265 billion, marginally missing the consensus of $1.269 billion. Adjusted EPS loss was $(1.46), down from $(0.82), missing the consensus of $(1.45).
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Perficient, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFT#NASDAQ">PRFT</a>) shares shot up 53% to $73.38 after the company disclosed an acquisition deal and first-quarter FY24 results.</li>
<li>Shares of Strong Global Entertainment, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGE#NYSE">SGE</a>) got a boost, surging 120% to $2.51  after FG Acquisition Corp. announced the proposed acquisition of Strong/MDI Screen Systems and the launch of Saltire Holdings.</li>
<li>XBP Europe Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBP#NASDAQ">XBP</a>) shares were also up, gaining 55% to $3.2680. XBP Europe Holdings was recently awarded a $40 million multi-year contract for a nationwide transformation project for His Majesty&#8217;s Passport Office.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Lyra Therapeutics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) shares dropped 87% to $3.2680 after the company announced the ENLIGHTEN 1 trial did not meet its primary endpoint.</li>
<li>Shares of GlycoMimetics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) were down 82% to $0.3330 after the company announced topline results from its Phase 3 global pivotal study of uproleselan in relapsed/refractory acute myeloid leukemia (R/R AML).</li>
<li>EyePoint Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>) was down, falling 42% to $11.38 after the company&#8217;s Phase 2 PAVIA trial of DURAVYU did not meet its pre-specified primary endpoint.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/news/24/05/38641330/netflix-home-depot-and-more-on-cnbcs-final-trades">Netflix, Home Depot And More On CNBC&#8217;s &#8216;Final Trades&#8217;</a>
Commodities In commodity news, oil traded up 0.6% to $78.56 while gold traded up 1.1% at $2,333.60.
Silver traded up 3.6% to $27.66 on Monday, while copper rose 1.1% to $4.6085.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.53%, Germany's DAX rose 0.96% and France's CAC 40 gained 0.49%. Spain's IBEX 35 Index rose 0.58%, while London's FTSE 100 rose 0.51%.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei falling 0.1%, Hong Kong's Hang Seng Index jumping 0.55% and India's S&amp;P BSE Sensex rising 0.02%.
Economics
No major economic reports will be released today.
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/05/38641042/how-to-earn-500-a-month-from-fmc-stock-ahead-of-q1-earnings">How To Earn $500 A Month From FMC Stock Ahead Of Q1 Earnings</a>

Earnings

Eurozone

Commodities

Intraday Update

EYPT

LYRA

PRFT

SAVE

Dow Surges Over 100 Points; EyePoint Pharmaceuticals Shares Plunge

HC Wainwright &amp; Co. analyst Edward White downgrades GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) from Buy to Neutral.

HC Wainwright & Co. Downgrades GlycoMimetics to Neutral

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Monday.
The Dow traded up 0.18% to 38,744.60 while the NASDAQ rose 0.69% to 16,267.82. The S&amp;P 500 also rose, gaining, 0.61% to 5,158.84.
Check This Out: <a href="https://www.benzinga.com/news/24/05/38611902/wall-streets-most-accurate-analysts-views-on-3-tech-telecom-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts&#8217; Views On 3 Tech &amp; Telecom Stocks Delivering High-Dividend Yields</a>
Leading and Lagging Sectors Energy shares rose by 1.5% on Monday.
In trading on Friday, consumer staples shares fell by 0.4%.
Top Headline
Shares of TreeHouse Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THS#NYSE">THS</a>) fell around 9% on Monday after the company reported mixed first-quarter financial results.
The company reported a first-quarter FY24 sales of $820.70 million, beating the analyst consensus estimate of $797.18 million. Adjusted EPS of $(0.03) missed the analyst consensus of $(0.01).
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Perficient, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFT#NASDAQ">PRFT</a>) shares shot up 53% to $73.53 after the company disclosed an acquisition deal and first-quarter FY24 results.</li>
<li>Shares of Strong Global Entertainment, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGE#NYSE">SGE</a>) got a boost, surging 108% to $2.3783 fter FG Acquisition Corp. announced the proposed acquisition of Strong/MDI Screen Systems and the launch of Saltire Holdings.</li>
<li>XBP Europe Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBP#NASDAQ">XBP</a>) shares were also up, gaining 53% to $3.2350. XBP Europe Holdings was recently awarded a $40 million multi-year contract for a nationwide transformation project for His Majesty&#8217;s Passport Office.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Lyra Therapeutics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) shares dropped 87% to $0.5363 after the company announced the ENLIGHTEN 1 trial did not meet its primary endpoint.</li>
<li>Shares of GlycoMimetics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) were down 79% to $0.3801 after the company announced topline results from its Phase 3 global pivotal study of uproleselan in relapsed/refractory acute myeloid leukemia (R/R AML).</li>
<li>EyePoint Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>) was down, falling 39% to $11.99 after the company&#8217;s Phase 2 PAVIA trial of DURAVYU did not meet its pre-specified primary endpoint.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/news/24/05/38611794/top-2-consumer-stocks-that-may-plunge-this-quarter&quot;">Top 2 Consumer Stocks That May Plunge This Quarter</a>
Commodities In commodity news, oil traded up 1.1% to $78.95 while gold traded up 1.2% at $2,335.40.
Silver traded up 3.6% to $27.645 on Monday, while copper rose 1.4% to $4.6225.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.53%, Germany's DAX rose 0.96% and France's CAC 40 gained 0.49%. Spain's IBEX 35 Index rose 0.58%, while London's FTSE 100 rose 0.51%.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei falling 0.1%, Hong Kong's Hang Seng Index jumping 0.55% and India's S&amp;P BSE Sensex rising 0.02%.
Economics
No major economic reports will be released today.
Now Read This: <a href="https://www.benzinga.com/news/24/05/38641330/netflix-home-depot-and-more-on-cnbcs-final-trades">Netflix, Home Depot And More On CNBC&#8217;s &#8216;Final Trades</a>&#8216;

Crude Oil Gains 1%; TreeHouse Foods Shares Fall After Q1 Results

<h3>Gainers</h3>
<ul>
<li>NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) shares increased by 39.5% to $2.93 during Monday's regular session. The company's market cap stands at $30.9 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) stock moved upwards by 35.61% to $1.98. The company's market cap stands at $6.3 million. </li>
<li>Outset Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) stock rose 26.15% to $3.96. The company's market cap stands at $204.8 million. </li>
<li>Nanoviricides (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#AMEX">NNVC</a>) stock moved upwards by 25.66% to $1.42. The market value of their outstanding shares is at $16.7 million. </li>
<li>Chemomab Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMMB#NASDAQ">CMMB</a>) stock rose 22.16% to $0.9. The market value of their outstanding shares is at $12.8 million. </li>
<li>Titan Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTNP#NASDAQ">TTNP</a>) shares moved upwards by 22.09% to $8.4. The market value of their outstanding shares is at $7.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) shares decreased by 86.3% to $0.55 during Monday's regular session. The market value of their outstanding shares is at $33.6 million. As per the news, the Q1 earnings report came out 4 days ago. </li>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) stock declined by 79.04% to $0.38. The market value of their outstanding shares is at $24.7 million. </li>
<li>EyePoint Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>) shares declined by 39.37% to $11.97. The market value of their outstanding shares is at $623.4 million. </li>
<li>Acutus Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFIB#NASDAQ">AFIB</a>) stock fell 27.1% to $0.11. The company's market cap stands at $3.1 million. </li>
<li>Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) shares declined by 20.46% to $22.98. The company's market cap stands at $1.8 billion. The company's, Q1 earnings came out today. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares fell 14.81% to $2.44. The company's market cap stands at $2.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AFIB

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

HSDT

IART

NNVC

NRXP

TCBP

TTNP

12 Health Care Stocks Moving In Monday's Intraday Session

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points on Monday.
The Dow traded up 0.25% to 38,772.28 while the NASDAQ rose 0.64% to 16,260.19. The S&amp;P 500 also rose, gaining, 0.59% to 5,157.96.
Check This Out: <a href="https://www.benzinga.com/news/24/05/38611902/wall-streets-most-accurate-analysts-views-on-3-tech-telecom-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts&#8217; Views On 3 Tech &amp; Telecom Stocks Delivering High-Dividend Yields</a>
Leading and Lagging Sectors Energy shares rose by 1.5% on Monday.
In trading on Friday, consumer staples shares fell by 0.4%.
Top Headline
Tyson Foods Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) reported weaker-than-expected sales for its second quarter.
The company posted a second-quarter FY24 sales decline of 0.46% year-on-year to $13.072 billion, missing the analyst consensus estimate of $13.157 billion. Adjusted EPS of 62 cents beat the consensus estimate of 39 cents.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Holdco Nuvo Group D.G Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVO#NASDAQ">NUVO</a>) shares shot up 222% to $6.57.</li>
<li>Shares of Strong Global Entertainment, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGE#NYSE">SGE</a>) got a boost, surging 150% to $2.84 fter FG Acquisition Corp. announced the proposed acquisition of Strong/MDI Screen Systems and the launch of Saltire Holdings.</li>
<li>XBP Europe Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XBP#NASDAQ">XBP</a>) shares were also up, gaining 62% to $3.4293. XBP Europe Holdings was recently awarded a $40 million multi-year contract for a nationwide transformation project for His Majesty&#8217;s Passport Office.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Lyra Therapeutics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) shares dropped 90% to $0.4013 after the company announced the ENLIGHTEN 1 trial did not meet its primary endpoint.</li>
<li>Shares of GlycoMimetics, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) were down 79% to $0.3831 after the company announced topline results from its Phase 3 global pivotal study of uproleselan in relapsed/refractory acute myeloid leukemia (R/R AML).</li>
<li>EyePoint Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>) was down, falling 39% to $11.99 after the company&#8217;s Phase 2 PAVIA trial of DURAVYU did not meet its pre-specified primary endpoint.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/news/24/05/38611794/top-2-consumer-stocks-that-may-plunge-this-quarter">Top 2 Consumer Stocks That May Plunge This Quarter</a>
Commodities In commodity news, oil traded up 0.7% to $78.63 while gold traded up 0.9% at $2,329.90.
Silver traded up 2.9% to $27.45 on Monday, while copper rose 1.3% to $4.6165.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 0.5%, Germany's DAX rose 0.9% and France's CAC 40 gained 0.4%. Spain's IBEX 35 Index rose 0.5%, while London's FTSE 100 rose 0.5%.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei falling 0.1%, Hong Kong's Hang Seng Index jumping 0.55% and India's S&amp;P BSE Sensex rising 0.02%.
Economics
No major economic reports will be released today.

NUVO

Nasdaq Jumps 100 Points; Tyson Foods Sales Miss Views

On Monday, GlycoMimetics Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) announced topline results from its Phase 3 global pivotal study of&nbsp;uproleselan&nbsp;in relapsed/refractory&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/b38636269/glycomimetics-announces-results-of-pivotal-phase-3-study-of-uproleselan-in-relapsedrefractory-rr-a" rel="noreferrer noopener">acute myeloid leukemia (R/R AML)</a>.&nbsp;
In the study,&nbsp;uproleselan&nbsp;combined with chemotherapy did not achieve a statistically significant improvement in overall survival&nbsp;in&nbsp;the intent to treat population versus chemotherapy alone.
Patients treated with&nbsp;uproleselan&nbsp;had a median overall survival of 13 months, compared to 12.3 months in the placebo arm. Adverse events were consistent with known side effect profiles of chemotherapy used in the study.
&#8220;We are thoroughly analyzing the data in collaboration with medical, statistical&nbsp;and&nbsp;regulatory experts and are committed to submitting a comprehensive data analysis for presentation at an upcoming medical meeting,&#8221; said Harout Semerjian, Chief Executive Officer of GlycoMimetics.&nbsp;
The 388-patient phase 3 study evaluated&nbsp;uproleselan&nbsp;in combination with MEC (mitoxantrone, etoposide, and cytarabine) or FAI (fludarabine, cytarabine, and idarubicin) in patients with R/R AML.&nbsp;
<ul>
<li>Patients received either uproleselan or placebo for 8 days over 1 cycle of induction and, if applicable, up to 3 cycles of consolidation. </li>
<li>The primary endpoint of the study was overall survival without censoring for transplant. </li>
<li>Secondary endpoints included incidence of severe oral mucositis, complete remission, and remission rates. </li>
</ul>
The NCI and the Alliance for Clinical Trials in Oncology are conducting an adaptive Phase 2/3 study of&nbsp;uproleselan&nbsp;in adults with newly diagnosed AML who are 60 years or older and fit for intensive chemotherapy.&nbsp;
<ul>
<li>The Phase 2 portion of the study completed enrollment of 267 patients in December 2021. The pre-planned Phase 2 event-free survival interim analysis results will be reported when available.</li>
</ul>
The company also disclosed cash and cash equivalents of $31.3 million, compared to $41.8 million&nbsp;as of&nbsp;December 31, 2023.
The company&#8217;s R&amp;D expenses increased to $6.0 million from $5.4 million a year ago, while G&amp;A expenses were $5.1 million, compared to $5.5 million a year ago.
Price Action: At last check on Monday, GLYC shares were down 78.2% at $0.39 during the premarket session.
Photo by PublicDomainPictures from Pixabay

GlycoMimetics' Uproleselan Flunks In Late Stage Leukemia Study, Shares Sink

<h3>Gainers</h3>
<ul>
<li>Monogram Orthopaedics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRM#NASDAQ">MGRM</a>) stock increased by 19.1% to $2.31 during Monday's pre-market session. The company's market cap stands at $73.1 million. </li>
<li>Allarity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLR#NASDAQ">ALLR</a>) shares moved upwards by 13.99% to $1.14. The market value of their outstanding shares is at $2.2 million. </li>
<li>VYNE Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) shares increased by 13.74% to $2.98. The company's market cap stands at $42.0 million. </li>
<li>Allogene Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLO#NASDAQ">ALLO</a>) stock increased by 13.02% to $3.47. The market value of their outstanding shares is at $592.4 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) stock rose 12.55% to $0.95. </li>
<li>Addex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) shares increased by 12.4% to $10.06. The company's market cap stands at $10.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) shares decreased by 78.7% to $0.39 during Monday's pre-market session. The market value of their outstanding shares is at $25.0 million. </li>
<li>Acutus Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFIB#NASDAQ">AFIB</a>) shares fell 38.57% to $0.09. The market value of their outstanding shares is at $2.6 million. </li>
<li>EyePoint Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>) shares declined by 33.29% to $13.17. The market value of their outstanding shares is at $685.9 million. </li>
<li>NeuBase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBSE#NASDAQ">NBSE</a>) shares fell 16.47% to $0.34. The company's market cap stands at $1.2 million. </li>
<li>Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) shares declined by 15.08% to $5.24. The market value of their outstanding shares is at $810.7 million. </li>
<li>Predictive Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) stock fell 13.82% to $1.56. The company's market cap stands at $6.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADXN

ALLO

ALLR

MGRM

NBSE

OCUL

POAI

SBFM

VYNE

12 Health Care Stocks Moving In Monday's Pre-Market Session

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Tuesday as we get into all of the hottest news worth reading about this morning!



Moving stocks this morning are earnings reports, insider buying, offerings and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Volcon (NASDAQ:<a href="https://investorplace.com/stock-quotes/vlcn-stock-quote/">VLCN</a>) stock is rocketing more than 78% alongside heavy pre-market trading.</li>



<li>Senti Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/snti-stock-quote/">SNTI</a>) shares are soaring over 47% with strong early morning trading.</li>



<li>GlycoMimetics (NASDAQ:<a href="https://investorplace.com/stock-quotes/glyc-stock-quote/">GLYC</a>) stock is surging more than 39% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318411360&amp;type=PDF&amp;symbol=GLYC&amp;cdn=8f7645b9da4ce31c36360d7737c007dc&amp;companyName=GlycoMimetics+Inc.&amp;formType=4&amp;formDescription=Statement+of+changes+in+beneficial+ownership+of+securities&amp;dateFiled=2024-06-24">alongside insider buying</a>.</li>



<li>Anew Medical (OTCMKTS:<a href="https://investorplace.com/stock-quotes/leas-stock-quote/">LEAS</a>) shares are gaining over 38% without any clear news this morning.</li>



<li>Nukkleus (NASDAQ:<a href="https://investorplace.com/stock-quotes/nukk-stock-quote/">NUKK</a>) shares are increasing more than 24% with strong pre-market trading.</li>



<li>Regis (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgs-stock-quote/">RGS</a>) stock is rising over 21% after announcing a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318412499&amp;type=PDF&amp;symbol=RGS&amp;cdn=4f01bbb678bba4ddafaac79f77ec0544&amp;companyName=Regis+Corporation&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-25">senior secured credit facility</a>.</li>



<li>Netcapital (NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>) shares are heading close to 20% higher with heavy pre-market trading today.</li>



<li>Kaival Brands Innovations (NASDAQ:<a href="https://investorplace.com/stock-quotes/kavl-stock-quote/">KAVL</a>) stock is jumping more than 17% <a href="https://www.nasdaq.com/press-release/kaival-brands-announces-closing-60-million-public-offering-2024-06-24">after closing a public offering</a>.</li>



<li>BioXcel Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/btai-stock-quote/">BTAI</a>) shares are climbing over 13% on <a href="https://www.nasdaq.com/press-release/bioxcel-therapeutics-announces-positive-topline-results-post-marketing-requirement">topline results from a study</a>.</li>



<li>Captivision (NASDAQ:<a href="https://investorplace.com/stock-quotes/capt-stock-quote/">CAPT</a>) stock is up more than 12% on Tuesday morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Faraday Future (NASDAQ:<a href="https://investorplace.com/stock-quotes/ffie-stock-quote/">FFIE</a>) stock is plummeting over 25% on plans for a <a href="https://finance.yahoo.com/news/faraday-future-announces-plans-regaining-215900667.html">reverse stock split</a>.</li>



<li>Concord Medical Services (NYSE:<a href="https://investorplace.com/stock-quotes/ccm-stock-quote/">CCM</a>) shares are diving more than 22% after a massive rally yesterday.</li>



<li>Beyond Air (NASDAQ:<a href="https://investorplace.com/stock-quotes/xair-stock-quote/">XAIR</a>) stock is tumbling over 19% on <a href="https://finance.yahoo.com/news/beyond-air-inc-xair-reports-212503389.html">lackluster Q4 earnings</a>.</li>



<li>MicroAlgo (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlgo-stock-quote/">MLGO</a>) shares are retreating more than 19% <a href="https://investorplace.com/2024/06/why-is-microalgo-mlgo-stock-up-113-today/">after rallying yesterday</a>.</li>



<li>SolarEdge Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/sedg-stock-quote/">SEDG</a>) stock is taking an over 16% beating on a <a href="https://www.nasdaq.com/press-release/solaredge-technologies-inc-announces-proposed-private-offering-300-million">$300 million private offering</a>.</li>



<li>IGC Pharma (NYSEMKT:<a href="https://investorplace.com/stock-quotes/igc-stock-quote/">IGC</a>) shares are dropping more than 16% on its <a href="https://www.nasdaq.com/press-release/igc-reports-financial-results-fiscal-year-ended-march-31-2024-2024-06-24">latest earnings report</a>.</li>



<li>Oragenics (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ogen-stock-quote/">OGEN</a>) stock is falling over 15% on a <a href="https://www.stocktitan.net/news/OGEN/oragenics-inc-announces-proposed-public-688vwqnwez4o.html">proposed public offering</a>.</li>



<li>DermTech (NASDAQ:<a href="https://investorplace.com/stock-quotes/dmtk-stock-quote/">DMTK</a>) shares are decreasing nearly 12% after a <a href="https://www.nasdaq.com/press-release/dermtech-files-voluntary-chapter-11-protection-2024-06-18">recent bankruptcy filing</a>.</li>



<li>Professional Diversity (NASDAQ:<a href="https://investorplace.com/stock-quotes/ipdn-stock-quote/">IPDN</a>) stock is slipping more than 11% with recent weakness.</li>



<li>36KR (NASDAQ:<a href="https://investorplace.com/stock-quotes/krkr-stock-quote/">KRKR</a>) shares close out our pre-market stock movers down over 10%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-june-25th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers as we check out all of the latest news happening on Wednesday morning!



Moving stocks this morning are patent news, a new investment, proposed public offerings and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Syntec Optics (NASDAQ:<a href="https://investorplace.com/stock-quotes/optx-stock-quote/">OPTX</a>) stock is rocketing more than 248% alongside heavy pre-market trading.</li>



<li>Anew Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/wena-stock-quote/">WENA</a>) shares are soaring over 75% after <a href="https://www.nasdaq.com/press-release/anew-medical-inc-secures-key-patent-europe-human-klotho-gene-rna-slice-variant-and">securing a key patent in Europe</a>.</li>



<li>Volcon (NASDAQ:<a href="https://investorplace.com/stock-quotes/vlcn-stock-quote/">VLCN</a>) stock is surging more than 36% as it <a href="https://investorplace.com/2024/06/why-is-volcon-vlcn-stock-up-60-today/">continues yesterday&rsquo;s rally</a>.</li>



<li>Rivian Automotive (NASDAQ:<a href="https://investorplace.com/stock-quotes/rivn-stock-quote/">RIVN</a>) shares are gaining over 36% on a <a href="https://www.nytimes.com/2024/06/25/business/volkswagen-rivian-vw-investment.html">$5 billion investment</a>.</li>



<li>China Natural Resources (NASDAQ:<a href="https://investorplace.com/stock-quotes/chnr-stock-quote/">CHNR</a>) stock is increasing more than 32% with strong trading this morning.</li>



<li>Savara (NASDAQ:<a href="https://investorplace.com/stock-quotes/svra-stock-quote/">SVRA</a>) shares are rising over 26% on a <a href="https://seekingalpha.com/news/4119362-savara-stock-surges-trial-win-lead-asset?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain">positive clinical trial</a>.</li>



<li>Talphera (NASDAQ:<a href="https://investorplace.com/stock-quotes/tlph-stock-quote/">TLPH</a>) stock is heading more than 21% higher on Wednesday morning.</li>



<li>eFFECTOR Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/eftr-stock-quote/">EFTR</a>) shares are climbing over 18% even as it plans to <a href="https://finance.yahoo.com/news/effector-therapeutics-announces-wind-down-110000717.html">wind down operations</a>.</li>



<li>Golden Matrix (NASDAQ:<a href="https://investorplace.com/stock-quotes/gmgi-stock-quote/">GMGI</a>) stock is jumping more than 15% today.</li>



<li>Faraday Future (NASDAQ:<a href="https://investorplace.com/stock-quotes/ffie-stock-quote/">FFIE</a>) shares are up over 14% <a href="https://investorplace.com/2024/06/faraday-future-stock-shocker-from-ev-maker-to-china-u-s-auto-middleman/">on survival plans</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>NextTrip (NASDAQ:<a href="https://investorplace.com/stock-quotes/ntrp-stock-quote/">NTRP</a>) stock is diving more than 24% without any recent news to report.</li>



<li>GRI Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/gri-stock-quote/">GRI</a>) shares are tumbling over 15% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318415310&amp;type=PDF&amp;symbol=GRI&amp;cdn=40db9b65c5660c095bf51f08f72c725f&amp;companyName=GRI+Bio+Inc.&amp;formType=S-1%2FA&amp;formDescription=%5BAmend%5D+General+form+for+registration+of+securities+under+the+Securities+Act+of+1933&amp;dateFiled=2024-06-26">proposed public offering</a>.</li>



<li>Taysha Gene Therapies (NASDAQ:<a href="https://investorplace.com/stock-quotes/tsha-stock-quote/">TSHA</a>) stock is taking a 14% beating on <a href="https://www.nasdaq.com/press-release/taysha-gene-therapies-announces-proposed-public-offering-common-stock-and-pre-funded">public offering plans</a>.</li>



<li>Oblong (NASDAQ:<a href="https://investorplace.com/stock-quotes/oblg-stock-quote/">OBLG</a>) shares are sliding more than 12% despite a lack of news this morning.</li>



<li>Hanryu (NASDAQ:<a href="https://investorplace.com/stock-quotes/hryu-stock-quote/">HRYU</a>) stock is decreasing over 11% on Wednesday.</li>



<li>Hamilton Beach Brands (NYSE:<a href="https://investorplace.com/stock-quotes/hbb-stock-quote/">HBB</a>) shares are dropping more than 10% today.</li>



<li>GlycoMimetics (NASDAQ:<a href="https://investorplace.com/stock-quotes/glyc-stock-quote/">GLYC</a>) stock is falling over 10% <a href="https://finance.yahoo.com/news/senior-vp-chief-medical-officer-100744620.html">despite insider buying</a>.</li>



<li>Geovax Labs (NASDAQ:<a href="https://investorplace.com/stock-quotes/govx-stock-quote/">GOVX</a>) shares are slipping more than 9% today.</li>



<li>Concord Medical Services (NYSE:<a href="https://investorplace.com/stock-quotes/ccm-stock-quote/">CCM</a>) stock is dipping over 9% this morning.</li>



<li>DermTech (NASDAQ:<a href="https://investorplace.com/stock-quotes/dmtk-stock-quote/">DMTK</a>) shares close out our pre-market stock movers down more than 9% as they <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318404814&amp;type=PDF&amp;symbol=DMTK&amp;cdn=2f95604b7d0b2db1ef0d52c1cc04ae14&amp;companyName=DermTech+Inc&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-20">prepare for delisting tomorrow</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-june-26th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
<a href="https://investorplace.com/industries/healthcare/biotech/">Biotech stocks</a> are not for everyone, let&rsquo;s make that perfectly clear. It&rsquo;s challenging to invest in a field in which companies &ndash; particularly startups &ndash; can go for years without seeing a penny of revenue. 



While there are several outstanding companies from which to choose, the field is also littered with biotech stocks to sell before you get in too much trouble.



Biotech stocks represent companies that are in the medical field. They develop and commercialize new medical treatments, drugs, and technologies, working in the fields of gene therapy, personalized medicine and biologics.



The challenge in this sector is that it takes a long time to bring a new drug or therapy to market. 



Even after the drug or therapy is discovered and developed in a laboratory setting, biotech companies must undergo preclinical research and a series of clinical trials. All these trials must be successful to go to the next step in the process. 



Clinical trials can often be expensive and time-consuming. And if the drug or therapy passes all of that, it still needs to get approval from the Food and Drug Administration (and regulators in other countries) before it can be brought to market.



Well-established biotech companies that have a history of success can better withstand these issues if they&rsquo;ve previously brought drugs to market and are bringing in revenue. 



But for a new company that doesn&rsquo;t have a revenue stream, clinical trials can try the patience of any investor &ndash; particularly as a company goes deeper into debt.



The biotech stocks we&rsquo;re looking at today all have good ideas, but the hurdles they have to clear to turn the corner are extremely high. 



If you&rsquo;re going to invest in the biotech sector, you should consider avoiding these names &ndash; and if you&rsquo;re an investor, you should take this opportunity to recognize biotech stocks to sell now.



<h2>Ginkgo Bioworks (DNA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/08/dna_ginkobioworks1600-300x169.png" alt="Person holding mobile phone with logo of American biotechnology company Ginkgo Bioworks Inc. on screen in front of web page. Focus on phone display. Unmodified photo. DNA stock"><div>Source: T. Schneider / Shutterstock.com</div></div>Ginkgo Bioworks (NYSE:<a href="https://investorplace.com/stock-quotes/dna-stock-quote/">DNA</a>) is a Boston-based company that uses genetic engineering to produce bacteria with industrial applications for other biotech companies.



The company specializes in cell programming and biosecurity. It&rsquo;s <a href="https://finance.yahoo.com/news/ginkgo-bioworks-novo-nordisk-expand-110200616.html">working</a> with Dutch biotech company Novo Nordisk (NYSE:<a href="https://investorplace.com/stock-quotes/nvo-stock-quote/">NVO</a>) on several research and development projects over the next five years, including diabetes and obesity medications.



Ginkgo also <a href="https://www.syngenta.com/en/company/media/syngenta-news/year/2024/syngenta-collaborates-ginkgo-bioworks-enable-faster-launch">announced</a> a collaboration with agricultural company Syngenta to develop and optimize a microbial strain for a secondary metabolite in Syngenta&rsquo;s pipeline.



As promising as these sound, the reality doesn&rsquo;t match up. DNA stock is down 82% this year and the company has just been trying to maintain its New York Stock Exchange <a href="http://investors.ginkgobioworks.com/news/news-details/2024/Ginkgo-Bioworks-Receives-Continued-Listing-Standard-Notice-From-NYSE/default.aspx">listing compliance</a>.



The company also instituted deep staff cuts, <a href="https://investorplace.com/2024/06/ginkgo-bioworks-layoffs-expand-to-400-job-cuts/">laying off</a> at least 35% of its 1,200-member workforce. &nbsp;



Revenue in the first quarter was $38 million, down from $81 million in the first quarter of 2023. Overall, the company reported a loss of $178 million for the quarter.



DNA stock gets an &ldquo;F&rdquo; rating in the Portfolio Grader.



<h2>Tonix Pharmaceuticals (TNXP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/pharmaceuticals_tnxp_1600-300x169.png" alt="medicine research, pharmaceutical background, LJPC stock"><div>Source: Sisacorn / Shutterstock.com</div></div>Tonix Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/txnp-stock-quote/">TXNP</a>) is making drugs and therapies to treat central nervous system disorders. But like many other biotech companies, it&rsquo;s paying the bills is a challenge.



Tonix hasn&rsquo;t yet brought a drug to market. It does have a candidate in Phase 3 testing as a treatment for fibromyalgia. The company is hoping for FDA approval for its drug, Tonmya, in the second half 2025.



Tonix also has a therapy in Phase 2 trials that would treat long Covid-19 symptoms, but Tonmya is much closer to becoming a reality.



That&rsquo;s why the company&rsquo;s trying to raise money. It had&nbsp;<a href="https://ir.tonixpharma.com/news-events/press-releases/detail/1490/tonix-pharmaceuticals-announces-closing-of-4-0-million">two separate $4 million public offerings in June</a>&nbsp;that will help, but also served to dilute investor equity. It also completed a 1-for-32 reverse stock split to regain Nasdaq listing compliance.



Tonix recorded a <a href="https://ir.tonixpharma.com/news-events/press-releases/detail/1469/tonix-pharmaceuticals-reports-first-quarter-2024-financial">net loss of $14.9 million in the first quarter,</a>&nbsp;or 18 cents per share. It only had $7 million in cash on hand at the end of the quarter, so it needs all the money it can get from its fundraising efforts.



TNXP stock is already back below $1 per share, having dropped 93% in 2024. It gets an &ldquo;F&rdquo; rating in the Portfolio Grader.



Tonix stock is down 95% this year, getting an &ldquo;F&rsquo; rating in the Portfolio Grader.



<h2>Gain Therapeutics (GANX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/03/ibio1600-300x169.jpg" alt="A scientist in medical gear peers through a microscope. IBIO stock"><div>Source: Shutterstock</div></div>Gain Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ganx-stock-quote/">GANX</a>) is a Maryland company that is developing possible therapies for neurodegenerative diseases, genetic disorders and cancer. 



The company lead candidate, which is in Phase 1 trials, has the potential to treat Parkinson&rsquo;s disease and other neurodegenerative diseases such as Gaucher disease, and Alzheimer&rsquo;s disease.



Gain also has a drug discovery platform called Magellan that uses artificial intelligence to help it develop therapies.



It&rsquo;s also trying to raise money, although doing so isn&rsquo;t a good deal for current shareholders. 



<a href="https://investorplace.com/2024/06/why-is-gain-therapeutics-ganx-stock-down-25-today/">Last month</a> it sold 7.11 million shares at $1.35 each in an effort to raise $11 million so it can continue testing its lead drug candidate. But the public offering also increased the number of shares in the company, which diluted shares.



It&rsquo;s also notable that CEO Matthias Alder abruptly left Gain in late June. He was replaced on an interim basis by Gene Mack, the chief financial officer.



All in all, Gain appears not to be on firm footing and is a long way from seeing revenue from its top drug candidate. The stock is down 62% this year and gets a &ldquo;D&rdquo; rating in the Portfolio Grader.



<h2>GlycoMimetics (GLYC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/bio1600-300x169.jpg" alt="MRNA Stock Will Continue Its Slump, but a $25 It Will Be a Great Buy"><div>Source: Shutterstock</div></div>GlycoMimetics (NASDAQ:<a href="https://investorplace.com/stock-quotes/glyc-stock-quote/">GLYC</a>) is another Maryland company. It&rsquo;s working on developing glycobiology-based therapies for cancer and inflammatory disease.



Glycobiology involves working with carbohydrates or sugar chains in an effort to develop appropriate therapies.



But the company took a major hit this spring when Phase 3 trials of its lead drug candidate failed to be statistically significant. The drug, uproleselan, was bring developed for the treatment of relapsed/refractory acute myeloid leukemia.



The company <a href="https://www.nasdaq.com/press-release/glycomimetics-announces-results-of-pivotal-phase-3-study-of-uproleselan-in-relapsed">noted</a> that the study didn&rsquo;t &ldquo;achieve a statistically significant improvement in overall survival in the intent to treat population versus chemotherapy alone.&rdquo; 



Patient survival reached a median of 13 months as compared to 12.3 months just with chemotherapy.



The company said it&rsquo;s planning to meet with regulators and the National Cancer Institute to determine a path forward. Meanwhile, the floor has fallen out from GLYC stock, which is down 87% on the year. It gets a &ldquo;D&rdquo; rating in the Portfolio Grader.



<h2>GRI Bio (GRI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biomedical-technology1600-300x169.png" alt="Modern Medical Research Laboratory with Computer, Microscope, Glassware with Biochemicals on the Desk. Scientific Lab Biotechnology Development Center Full of High-Tech Equipment. Biomedical technology stocks, RSLS Stock"><div>Source: Gorodenkoff / Shutterstock.com</div></div>GRI Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/gri-stock-quote/">GRI</a>) is developing therapies to treat inflammatory disease. 



Its&nbsp;therapies would target the activity of Natural Killer T (&ldquo;NKT&rdquo;) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression.



The company has four drug candidates in its pipeline, with the most advanced being a treatment for idiopathic pulmonary fibrosis. That candidate is in Phase 2 trials.



Like many other early-stage biotech companies, GRI Bio is trying to raise money to keep the doors open, while at the same time <a href="https://gribio.com/gri-bio-regains-compliance-with-nasdaq/">trying not to be delisted by the index</a>.



The company announced late last month that it would sell more than 2 million shares of GRI stock &ndash; an <a href="https://investorplace.com/2024/06/why-is-gri-bio-gri-stock-down-29-today/">announcement</a> that sent the stock price down by 29%.



GRI stock is now down 95% in 2024. It gets an &ldquo;F&rdquo; rating in the Portfolio Grader.



<h2>Ovid Therapeutics (OVID)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600d-300x169.jpg" alt="Image of two scientists in lab coats studying results in a lab. best biotech stocks to buy"><div>Source: Shutterstock</div></div>Ovid Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ovid-stock-quote/">OVID</a>) is a biotech company that is working to create therapies to combat neurological diseases. 



Its drug candidate to treat brainstem malformations completed Phase 1 trials, while three other drug candidates are not as far advanced.



Ovid also has a partnership with Takeda to bring another drug, soticlestat to market to treat Dravet syndrome and Lennox-Gastaut syndrome. 



Both therapies are in Phase 3 trials, but the top-line study results are not promising. 



The treatment for Dravet syndrome narrowly missed its primary endpoint in reducing the frequency of seizures, and its treatment for Lennox-Gastaut syndrome missed its mark in reducing motor drop seizures.



Ovid only had revenue of <a href="https://investors.ovidrx.com/news/news-details/2024/Ovid-Therapeutics-Reports-Business-Updates-and-First-Quarter-2024-Financial-Results/default.aspx">$148,000 in the first quarter</a> versus operating expenses of $17.2 million. The company has roughly $90 million of cash on hand, so it&rsquo;s not at immediate risk. But it&rsquo;s also a long way from turning a profit as well.



OVID stock is down 70% this year &ndash; with much of that drop coming after the Phase 3 trials on soticlestat were released. and gets a &ldquo;D&rdquo; rating in the Portfolio Grader.



<h2>Cosmos Health (<a href="https://investorplace.com/stock-quotes/cosm-stock-quote/">COSM</a>)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div>Cosmos Health (NASDASQ:<a href="https://investorplace.com/stock-quotes/cosm-stock-quote/">COSM</a>) is a Chicago company that serves as a holding company. 



Its portfolio includes pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe and C-Sept.



The company also operates a subsidiary, Cana Laboratories, to manufacture pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. 



The company makes and sells branded generics and over-the-counter medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the U.K.



The company has not yet filed its fourth-quarter report, and received a notice of noncompliance from Nasdaq for the failure. 



But its third-quarter report included a couple of red flags, including a drop in year-to-date revenue from $38.3 million to $37.5 million; and a drop in cash from $20.7 million to $2.3 million.



COSM stock is down 10% this year and gets a &ldquo;D&rdquo; rating in the Portfolio Grader.



On the date of publication, Louis Navellier had a long position in NVO. Louis Navellier did not have (either directly or indirectly) any other positions in the securities mentioned in this article.



InvestorPlace Research Staff member primarily responsible for this article did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://url.us.m.mimecastprotect.com/s/AAadCPNlWWs3yKYns0yRM6?domain=investorplace.com/">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) and positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/market360/2024/07/7-sorry-biotech-stocks-set-to-make-investors-sad-2/">7 Sorry Biotech Stocks Set to Make Investors Sad</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 Sorry Biotech Stocks Set to Make Investors Sad

GlycoMimetics to cut workforce by about 80% in corporate restructuring plan

In a report released today, Edward White from H.C. Wainwright maintained a Hold rating on GlycoMimetics (GLYC – Research Report). The company's sha...

H.C. Wainwright Remains a Hold on GlycoMimetics (GLYC)

GlycoMimetics (GLYC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Naureen Quibria from C...

GlycoMimetics: Strategic Overhaul and FDA Setback Justify Hold Rating

GlycoMimetics (GLYC – Research Report) received a Hold rating and price target from TD Cowen analyst Tara Bancroft today. The company's shares clos...

GlycoMimetics (GLYC) was downgraded to a Hold Rating at TD Cowen

GlycoMimetics (GLYC) just unveiled an update. GlycoMimetics, Inc. is implementing a new operating plan to enhance shareholder value, which includes...

GlycoMimetics Announces Strategic Review and Restructuring Plan

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Doximity (DOCS – Research Report), Avinger (AVGR –...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Doximity (DOCS), Avinger (AVGR) and GlycoMimetics (GLYC)

Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August

ABUS

ALPMF

ALPMY

ANTX

ATHA

AVGR

BAYRY

BAYZF

BBIO

BMRN

BTAI

CAPT

CDTX

CHNR

COSM

CRBU

CVAC

DMTK

DOCS

EFTR

FFIE

FGEN

GANX

GMGI

GOVX

HLVX

HRYU

IBRX

INAB

IPDN

KAVL

KRKR

LEAS

LXRX

MLGO

NCPL

NTRP

NUKK

OBLG

OGEN

OPTX

OVID

PGEN

QURE

RAPT

RHHBY

RIVN

RLAY

RPTX

SEDG

SLRN

SNTI

SVRA

TLPH

TSHA

VIRX

VLCN

WENA

XAIR

Press Releases

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference

GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024

GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023

GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024

GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Comments

GlycoMimetics

Vendite allo scoperto

GlycoMimetics (NASDAQ:GLYC) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO